157 related articles for article (PubMed ID: 24328939)
1. Melanoma associated with tumour necrosis factor-α inhibitors: a Research on Adverse Drug events And Reports (RADAR) project.
Nardone B; Hammel JA; Raisch DW; Weaver LL; Schneider D; West DP
Br J Dermatol; 2014 May; 170(5):1170-2. PubMed ID: 24328939
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
3. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
5. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
6. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Drug Saf; 2013 May; 36(5):329-34. PubMed ID: 23580194
[TBL] [Abstract][Full Text] [Related]
7. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
[TBL] [Abstract][Full Text] [Related]
8. The Risk of Glioblastoma with TNF Inhibitors.
Guo M; Luo H; Samii A; Etminan M
Pharmacotherapy; 2016 Apr; 36(4):449-54. PubMed ID: 26931498
[TBL] [Abstract][Full Text] [Related]
9. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Matsui T; Umetsu R; Kato Y; Hane Y; Sasaoka S; Motooka Y; Hatahira H; Abe J; Fukuda A; Naganuma M; Kinosada Y; Nakamura M
Int J Med Sci; 2017; 14(2):102-109. PubMed ID: 28260984
[TBL] [Abstract][Full Text] [Related]
10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
12. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
Jedlowski PM
Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
[TBL] [Abstract][Full Text] [Related]
13. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases.
Chen C; Borrego ME; Roberts MH; Raisch DW
Expert Opin Drug Saf; 2019 Aug; 18(8):733-744. PubMed ID: 31173698
[No Abstract] [Full Text] [Related]
14. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B
Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333
[TBL] [Abstract][Full Text] [Related]
15. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
Deepak P; Stobaugh DJ
Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
[TBL] [Abstract][Full Text] [Related]
16. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].
Kowalzick L; Eickenscheidt L; Komar M; Schaarschmidt E
Hautarzt; 2009 Aug; 60(8):655-7. PubMed ID: 19280165
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
18. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Joyau C; Veyrac G; Dixneuf V; Jolliet P
Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
